You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDextropropoxyphene
Accession NumberDB00647  (APRD00548)
TypeSmall Molecule
GroupsApproved, Illicit, Withdrawn
DescriptionDextropropoxyphene is an analgesic in the opioid category, patented (1955) and manufactured by Eli Lilly and Company. It is intended to treat mild pain and also has antitussive and local anaesthetic effects. The drug has been taken off the market in Europe and the US due to concerns of fatal overdoses and heart arrhythmias. An estimated 10 million patients have used these products. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect.
Structure
Thumb
Synonyms
d-Propoxyphene
Destropropossifene
Dextropropoxifeno
Dextropropoxyphen
Dextropropoxyphène
Dextropropoxyphenum
External Identifiers
  • L 16298
  • SK 65
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
642 TabTablet65 mgOralPendopharm Division Of De Pharmascience Inc1968-12-312010-11-25Canada
Darvon-NCapsule100 mgOralPaladin Labs Inc1973-12-312010-12-23Canada
Novo-propoxyn Cap 65mgCapsule65 mgOralNovopharm Limited1970-12-312005-08-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PropoxypheneCapsule65 mg/1OralStat Rx USA2009-10-27Not applicableUs
Propoxyphene HydrochlorideCapsule65 mg/1OralHeritage Pharmaceuticals Inc2009-05-01Not applicableUs
Propoxyphene HydrochlorideCapsule65 mg/1Oralbryant ranch prepack2009-12-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AbalginDLF
DacotonStandard
DarvonEli Lilly
DeprancolParke Davis
DepronalPfizer
DoleneNot Available
DoloxeneAspen Pharmacare
Brand mixtures
NameLabellerIngredients
692 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
692 TabletLioh Inc.
Darvon N Compound Pulvule 405Eli Lilly Canada Inc
Novo-propoxyn Compound CapNovopharm Limited
Propoxyphene Hydrochloride and AcetaminophenMylan Pharmaceuticals Inc.
Salts
Name/CASStructureProperties
Dextropropoxyphene Hydrochloride
1639-60-7
Thumb
  • InChI Key: QMQBBUPJKANITL-MYXGOWFTSA-N
  • Monoisotopic Mass: 375.196506916
  • Average Mass: 375.932
DBSALT000500
Dextropropoxyphene Napsylate
ThumbNot applicableDBSALT001000
Categories
UNIIS2F83W92TK
CAS number469-62-5
WeightAverage: 339.4712
Monoisotopic: 339.219829177
Chemical FormulaC22H29NO2
InChI KeyXLMALTXPSGQGBX-PEODTPIXNA-N
InChI
InChI=1/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/s2
IUPAC Name
(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl propanoate
SMILES
CCC(=O)O[C@@](CC1=CC=CC=C1)([[email protected]](C)CN(C)C)C1=CC=CC=C1
Pharmacology
IndicationFor the relief of mild to moderate pain
Structured Indications
PharmacodynamicsPropoxyphene, a synthetic opiate agonist, is structurally similar to methadone. Its general pharmacologic properties are those of the opiates as a group. The analgesic effect of propoxyphene is due to the d-isomer, dextropropoxyphene. It binds to the opiate receptors and leads to a decrease of the perception of pain stimuli. Propoxyphene possesses little to no antitussive activity and no antipyretic action.
Mechanism of actionPropoxyphene acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Propoxyphene primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as propoxyphene also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
agonist
HumanP35372 details
Delta-type opioid receptorProteinyes
agonist
HumanP41143 details
Kappa-type opioid receptorProteinyes
antagonist
HumanP41145 details
Related Articles
AbsorptionNot Available
Volume of distribution
  • 16 L/kg
Protein bindingNot Available
Metabolism

Hepatic

Route of eliminationThe major route of metabolism is cytochrome CYP3A4 mediated N-demethylation to norpropoxyphene, which is excreted by the kidneys. In 48 hours, approximately 20% to 25% of the administered dose of propoxyphene is excreted via the urine, most of which is free or conjugated norpropoxyphene.
Half life6-12 hours
Clearance
  • 2.6 L/min
ToxicityComa, respiratory depression, circulatory collapse, and pulmonary edema. Seizures occur more frequently in patients with propoxyphene intoxication than in those with opiate intoxication. LD50=230mg/kg (orally in rat, Emerson)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Propoxyphene Action PathwayDrug actionSMP00672
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Dextropropoxyphene.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dextropropoxyphene.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Dextropropoxyphene.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dextropropoxyphene.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dextropropoxyphene.Approved
adipiplonThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alfentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Dextropropoxyphene.Approved, Vet Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dextropropoxyphene.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amiloride.Approved
AmiodaroneThe metabolism of Dextropropoxyphene can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Dextropropoxyphene which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Dextropropoxyphene.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Dextropropoxyphene.Approved
AprepitantThe serum concentration of Dextropropoxyphene can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Asenapine.Approved
AtazanavirThe metabolism of Dextropropoxyphene can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Dextropropoxyphene can be decreased when combined with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dextropropoxyphene.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Dextropropoxyphene.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Azaperone.Vet Approved
AzelastineDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dextropropoxyphene.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dextropropoxyphene.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Benzyl alcohol.Approved
BexaroteneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Dextropropoxyphene.Approved
BL-1020BL-1020 may increase the hypotensive activities of Dextropropoxyphene.Investigational
BoceprevirThe metabolism of Dextropropoxyphene can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Dextropropoxyphene can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved
BromazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dextropropoxyphene.Approved, Investigational
BuprenorphineDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dextropropoxyphene.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dextropropoxyphene.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Butethal.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Dextropropoxyphene.Approved, Illicit, Vet Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Canrenone.Investigational
CarbamazepineThe metabolism of Dextropropoxyphene can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Dextropropoxyphene can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dextropropoxyphene.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Dextropropoxyphene.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Dextropropoxyphene.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dextropropoxyphene.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cicletanine.Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dextropropoxyphene.Approved, Vet Approved
CitalopramDextropropoxyphene may increase the serotonergic activities of Citalopram.Approved
ClarithromycinThe metabolism of Dextropropoxyphene can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Dextropropoxyphene can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dextropropoxyphene.Approved, Illicit
ClotrimazoleThe metabolism of Dextropropoxyphene can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dextropropoxyphene.Approved
CobicistatThe metabolism of Dextropropoxyphene can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dextropropoxyphene.Approved, Illicit
ConivaptanThe serum concentration of Dextropropoxyphene can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Dextropropoxyphene can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyclobenzaprine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dextropropoxyphene.Approved
CyclosporineThe metabolism of Dextropropoxyphene can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dextropropoxyphene.Approved
DapoxetineDextropropoxyphene may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dextropropoxyphene.Approved, Investigational
DarunavirThe metabolism of Dextropropoxyphene can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Dextropropoxyphene can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Dextropropoxyphene can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desmopressin.Approved
DesvenlafaxineDextropropoxyphene may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Dextropropoxyphene.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dextropropoxyphene.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dextromoramide.Experimental, Illicit
DezocineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Diazepam.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dextropropoxyphene.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Dextropropoxyphene can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Dextropropoxyphene can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Doxepin.Approved
DoxycyclineThe metabolism of Dextropropoxyphene can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Illicit
DronedaroneThe metabolism of Dextropropoxyphene can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Drotebanol.Experimental, Illicit
DuloxetineDextropropoxyphene may increase the serotonergic activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dextropropoxyphene.Approved
EcgonineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Efonidipine.Approved
EluxadolineDextropropoxyphene may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dextropropoxyphene.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Eplerenone.Approved
ErythromycinThe metabolism of Dextropropoxyphene can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramDextropropoxyphene may increase the serotonergic activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dextropropoxyphene.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etacrynic acid.Approved
EthanolDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Dextropropoxyphene.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dextropropoxyphene.Approved
EtoperidoneDextropropoxyphene may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dextropropoxyphene.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flibanserin.Approved
FluconazoleThe metabolism of Dextropropoxyphene can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flunitrazepam.Approved, Illicit
FluoxetineDextropropoxyphene may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dextropropoxyphene.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Dextropropoxyphene can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Dextropropoxyphene can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Dextropropoxyphene can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Dextropropoxyphene can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Dextropropoxyphene can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Dextropropoxyphene.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Dextropropoxyphene.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dextropropoxyphene.Approved
HalothaneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dextropropoxyphene.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Dextropropoxyphene.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dextropropoxyphene.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Dextropropoxyphene.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dextropropoxyphene.Approved
IdelalisibThe serum concentration of Dextropropoxyphene can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Iloperidone.Approved
ImatinibThe metabolism of Dextropropoxyphene can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Imipramine.Approved
IndalpineDextropropoxyphene may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Indapamide.Approved
IndinavirThe metabolism of Dextropropoxyphene can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dextropropoxyphene.Approved
IsavuconazoniumThe metabolism of Dextropropoxyphene can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Isoflurane.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Isosorbide.Approved
IsradipineThe metabolism of Dextropropoxyphene can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Dextropropoxyphene can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Dextropropoxyphene can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Dextropropoxyphene can be decreased when combined with Ketoconazole.Approved, Investigational
KW-3902The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with KW-3902.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levomethadyl Acetate.Approved
LevomilnacipranDextropropoxyphene may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dextropropoxyphene.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lofentanil.Illicit
LopinavirThe metabolism of Dextropropoxyphene can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dextropropoxyphene.Approved
LovastatinThe metabolism of Dextropropoxyphene can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dextropropoxyphene.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Dextropropoxyphene can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Dextropropoxyphene can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dextropropoxyphene.Approved
MeclizineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Dextropropoxyphene.Investigational
MephentermineMephentermine may increase the analgesic activities of Dextropropoxyphene.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dextropropoxyphene.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dextropropoxyphene.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Dextropropoxyphene.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dextropropoxyphene.Approved
MethotrimeprazineDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Dextropropoxyphene.Investigational
MethylnaltrexoneThe risk or severity of adverse effects can be increased when Methylnaltrexone is combined with Dextropropoxyphene.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methylphenobarbital.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Dextropropoxyphene.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Dextropropoxyphene.Approved, Investigational
MetyrosineDextropropoxyphene may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Dextropropoxyphene can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranDextropropoxyphene may increase the serotonergic activities of Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Investigational
MirtazapineDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Dextropropoxyphene.Experimental, Illicit
ModafinilThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Dextropropoxyphene.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dextropropoxyphene.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Dextropropoxyphene.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Investigational
NafcillinThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Dextropropoxyphene.Approved
NaloxegolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Naloxegol.Approved
NaltrexoneThe therapeutic efficacy of Dextropropoxyphene can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneThe metabolism of Dextropropoxyphene can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Dextropropoxyphene can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Dextropropoxyphene can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Dextropropoxyphene can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Dextropropoxyphene can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Dextropropoxyphene.Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dextropropoxyphene.Approved, Investigational
OlaparibThe metabolism of Dextropropoxyphene can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Opium.Approved, Illicit
OrphenadrineDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Dextropropoxyphene can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Dextropropoxyphene.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dextropropoxyphene.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dextropropoxyphene.Approved
PalbociclibThe serum concentration of Dextropropoxyphene can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Paliperidone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dextropropoxyphene.Approved
ParaldehydeDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineDextropropoxyphene may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextropropoxyphene.Approved
PentazocinePentazocine may decrease the analgesic activities of Dextropropoxyphene.Approved, Vet Approved
PentobarbitalThe metabolism of Dextropropoxyphene can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Dextropropoxyphene.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved
PerazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dextropropoxyphene.Approved
PhenobarbitalThe metabolism of Dextropropoxyphene can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Phenoxyethanol.Approved
PhenterminePhentermine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit
PhenytoinThe metabolism of Dextropropoxyphene can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dextropropoxyphene.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dextropropoxyphene.Approved
PiretanideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Dextropropoxyphene can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleDextropropoxyphene may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dextropropoxyphene.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Prilocaine.Approved
PrimidoneThe metabolism of Dextropropoxyphene can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dextropropoxyphene.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dextropropoxyphene.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dextropropoxyphene.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dextropropoxyphene.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Proparacaine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Dextropropoxyphene.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Dextropropoxyphene.Investigational
PropofolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Dextropropoxyphene.Approved
QuazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Dextropropoxyphene.Approved
RacloprideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ramelteon.Approved, Investigational
RamosetronDextropropoxyphene may increase the constipating activities of Ramosetron.Approved
RanolazineThe metabolism of Dextropropoxyphene can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dextropropoxyphene.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dextropropoxyphene.Approved
RifabutinThe metabolism of Dextropropoxyphene can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Dextropropoxyphene can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Dextropropoxyphene can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Dextropropoxyphene.Investigational
RitonavirThe metabolism of Dextropropoxyphene can be decreased when combined with Ritonavir.Approved, Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Romifidine.Vet Approved
RopiniroleDextropropoxyphene may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dextropropoxyphene.Approved
RotigotineDextropropoxyphene may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dextropropoxyphene.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sage 547.Investigational
SaquinavirThe metabolism of Dextropropoxyphene can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dextropropoxyphene.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dextropropoxyphene.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sertindole.Approved, Withdrawn
SertralineDextropropoxyphene may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Dextropropoxyphene can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Dextropropoxyphene can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Dextropropoxyphene.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Dextropropoxyphene can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Dextropropoxyphene can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Dextropropoxyphene.Approved
SufentanilThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Dextropropoxyphene can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dextropropoxyphene.Approved
SuvorexantDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Dextropropoxyphene can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Dextropropoxyphene can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dextropropoxyphene.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tetrodotoxin.Investigational
ThalidomideDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Dextropropoxyphene.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dextropropoxyphene.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Dextropropoxyphene.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tiapride.Investigational
TiclopidineThe metabolism of Dextropropoxyphene can be decreased when combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tiletamine.Vet Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Dextropropoxyphene.Approved
TizanidineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tolcapone.Approved, Withdrawn
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Dextropropoxyphene.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dextropropoxyphene.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trazodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triazolam.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dextropropoxyphene.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dextropropoxyphene.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Dextropropoxyphene.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Dextropropoxyphene.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Dextropropoxyphene.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Dextropropoxyphene.Approved
Uc1010The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Dextropropoxyphene.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dextropropoxyphene.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dextropropoxyphene.Approved
VenlafaxineThe metabolism of Dextropropoxyphene can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Dextropropoxyphene can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Dextropropoxyphene can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ziconotide.Approved
ZimelidineDextropropoxyphene may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Dextropropoxyphene can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zolazepam.Vet Approved
ZolpidemDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.
References
Synthesis Reference

Carl R. White, “Synthesis and purification of d-propoxyphene hydrochloride.” U.S. Patent US4661625, issued April, 1973.

US4661625
General References
  1. Coda BA, Rudy AC, Archer SM, Wermeling DP: Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesth Analg. 2003 Jul;97(1):117-23, table of contents. [PubMed:12818953 ]
External Links
ATC CodesN02AC54N02AC74N02AC04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (46.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.997
Blood Brain Barrier+0.9503
Caco-2 permeable+0.7277
P-glycoprotein substrateSubstrate0.5798
P-glycoprotein inhibitor IInhibitor0.7851
P-glycoprotein inhibitor IINon-inhibitor0.6469
Renal organic cation transporterNon-inhibitor0.6086
CYP450 2C9 substrateNon-substrate0.833
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.6032
CYP450 1A2 substrateInhibitor0.6357
CYP450 2C9 inhibitorNon-inhibitor0.7637
CYP450 2D6 inhibitorInhibitor0.6887
CYP450 2C19 inhibitorNon-inhibitor0.7628
CYP450 3A4 inhibitorNon-inhibitor0.7992
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.646
Ames testNon AMES toxic0.8896
CarcinogenicityCarcinogens 0.7164
BiodegradationNot ready biodegradable0.9714
Rat acute toxicity2.9360 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9033
hERG inhibition (predictor II)Inhibitor0.6837
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Xanodyne pharmaceutics inc
  • Heritage pharmaceuticals inc
  • Mk laboratories inc
  • Halsey drug co inc
  • Alra laboratories inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Nexgen pharma inc
  • Par pharmaceutical inc
  • Purepac pharmaceutical co
  • Private formulations inc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Valeant pharmaceuticals international
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Warner chilcott div warner lambert co
  • Aaipharma llc
Packagers
Dosage forms
FormRouteStrength
TabletOral65 mg
TabletOral
CapsuleOral
CapsuleOral100 mg
CapsuleOral65 mg
CapsuleOral65 mg/1
Tablet, film coatedOral
Prices
Unit descriptionCostUnit
Propoxyphene napsylate powder5.33USD g
Darvon-n 100 mg tablet2.16USD tablet
Darvon 65 mg capsule1.71USD capsule
Propoxyphene N-APAP 100-500 mg tablet1.6USD tablet
Darvon 65 mg pulvule1.49USD each
Propoxyphene N-APAP 50-325 mg tablet1.32USD tablet
Propoxyphene-APAP 65-650 mg tablet0.57USD tablet
Propoxyphene N-APAP 100-650 mg tablet0.47USD tablet
Propoxyphene hcl 65 mg capsule0.43USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point75.5 °CPhysProp
water solubility3.32 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP4.18HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00419 mg/mLALOGPS
logP4.06ALOGPS
logP4.9ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)9.52ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity102.88 m3·mol-1ChemAxon
Polarizability38.86 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-0a4i-9200000000-39d80ee06dde3e5036f4View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassStilbenes
Sub ClassNot Available
Direct ParentStilbenes
Alternative Parents
Substituents
  • Stilbene
  • Phenylbutylamine
  • Phenylpropylamine
  • Benzyloxycarbonyl
  • Phenylpropane
  • Aralkylamine
  • Benzenoid
  • Monocyclic benzene moiety
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
  • 1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate (CHEBI:51173 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Ulens C, Daenens P, Tytgat J: Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc Res. 1999 Dec;44(3):568-78. [PubMed:10690289 ]
  3. Tyers MB: A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol. 1980 Jul;69(3):503-12. [PubMed:6249436 ]
  4. Picker MJ: Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists. J Pharmacol Exp Ther. 1997 Dec;283(3):1009-17. [PubMed:9399970 ]
  5. Codd EE, Shank RP, Schupsky JJ, Raffa RB: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995 Sep;274(3):1263-70. [PubMed:7562497 ]
  6. Bannwarth B, Richez C: The dextropropoxyphene controversy. Joint Bone Spine. 2009 Oct;76(5):449-51. doi: 10.1016/j.jbspin.2009.04.004. Epub 2009 Jul 14. [PubMed:19604717 ]
  7. Walker EA, Tiano MJ, Benyas SI, Dykstra LA, Picker MJ: Naltrexone and beta-funaltrexamine antagonism of the antinociceptive and response rate-decreasing effects of morphine, dezocine, and d-propoxyphene. Psychopharmacology (Berl). 1999 May;144(1):45-53. [PubMed:10379623 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Neil A: Affinities of some common opioid analgesics towards four binding sites in mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1984 Nov;328(1):24-9. [PubMed:6151117 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Neil A: Affinities of some common opioid analgesics towards four binding sites in mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1984 Nov;328(1):24-9. [PubMed:6151117 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23